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Objective. The total haemolytic complement activity (CH50) assay evaluates the functioning of the complement system. 
Accumulating evidence indicates that the activation of the complement system plays a critical role in the pathogenesis of anti-
neutrophil cytoplasmic antibody-associated vasculitis (AAV). Therefore, this study aimed to investigate whether CH50 levels 
at diagnosis could reflect the baseline activity of AAV. Methods. This retrospective study included 101 immunosuppressive 
drug-naïve patients with AAV. At diagnosis, all patients underwent clinical assessments for disease activity, including measure-
ment of the Birmingham Vasculitis Activity Score (BVAS) and Five Factor Score (FFS), and laboratory evaluations, such as tests 
for CH50, C3, and C4 levels. The association between CH50 levels and disease activity was determined.  Results. The median 
BVAS and FFS at diagnosis were 12.0 and 1.0, respectively, whereas the median CH50 level was 60.4 U/mL. There was a neg-
ative correlation between the CH50 level and BVAS (r=−0.241; p=0.015). A CH50 cut-off value of 62.1 U/mL was used to 
classify the patients into two groups: patients with CH50 levels ＜62.1 U/mL (low-CH50 group) and those with CH50 levels ≥
62.1 U/mL (high-CH50 group). The low-CH50 group had a higher proportion of patients with high disease activity, based on 
the BVAS, than the high-CH50 group (52.5% vs. 23.8%, p=0.004). Additionally, the low-CH50 group exhibited a lower re-
lapse-free survival rate than the high-CH50 group; however, this difference was not statistically significant (p=0.082). 
Conclusion. Low CH50 levels at diagnosis may reflect high baseline activity of AAV. (J Rheum Dis 2021;28:85-93)
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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV) is characterised by necrotising vasculitis 
that affects small vessels, including arterioles, venules, 
and capillaries. The 2012 Chapel Hill Consensus 
Conference Nomenclature of the Vasculitides (the 2012 
CHCC definitions) and the 2007 European Medicines 
Agency algorithm (the 2007 EMA algorithm) indicated 
that AAV consists of three subtypes: microscopic poly-
angiitis (MPA), granulomatosis with polyangiitis (GPA), 
and eosinophilic granulomatosis with polyangiitis 
(EGPA) [1,2]. Although various immune mechanisms 
are involved in its pathogenesis, the alternative comple-
ment pathway is central to the acceleration and main-
tenance of the vicious inflammatory cycle of AAV [3,4]. 
Therefore, with the progression of inflammation, the 
consumption of complement components may be theo-
retically increased, resulting in hypocomplementemia. 
The total haemolytic complement activity (CH50) assay 
is a widely used assay to evaluate abnormalities of all 
complement components (C1 to C9). CH50 can be re-
duced owing to congenital complement deficiencies, in-
creased complement consumption, or decreased comple-
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ment synthesis [5]. In the pathogenesis of AAV, the alter-
native complement system is activated and generates 
C5a, which attracts and prime neutrophils [6]. Considering 
that CH50 assesses the overall activity of the whole com-
plement system, and that hypocomplementemia has been 
reported in patients with vasculitis and associated with 
the patient prognosis [7-10], we aimed to investigate 
whether CH50 at diagnosis reflects the baseline activity 
and predicts disease outcomes during follow-up in im-
munosuppressive drug-naïve AAV patients in this study. 
MATERIALS AND METHODS
Patients 
We included and reviewed the medical records of 101 
immunosuppressive drug-naïve patients with AAV who 
were evaluated at the tertiary medical center, between 
October 2000 and December 2019. All patients were clas-
sified or reclassified to have MPA, GPA, or EGPA based on 
the 2007 EMA algorithm and the 2012 CHCC definition 
[1,2]. All patients had well-documented medical records 
to obtain clinical and laboratory results and to calculate 
the Birmingham Vasculitis Activity Score (BVAS) and the 
Five Factor Score (FFS) at the time of diagnosis [11,12]. 
Additionally, all patient records had information for both 
tests for ANCA and complements, such as CH50, C3, and 
C4 [13,14], and all patients had been followed up for at 
least 3 months. None of the patients had any serious med-
ical condition, such as malignancies and serious in-
fections, at the time of diagnosis, and they had never re-
ceived any immunosuppressive drug until diagnosis. This 
study was approved by the Institutional Review Board of 
Severance Hospital (4-2017-0673). The need for written 
informed consent was waived owing to the retrospective 
nature of this study.
Clinical data at diagnosis and during follow-up
Regarding variables at diagnosis, information on age and 
sex was collected as demographic data. Clinical data, such 
as those on AAV subtypes, and those pertaining to dis-
ease activity, including the BVAS and FFS, were collected. 
Laboratory data, including those of white blood cell and 
platelet counts, haemoglobin, fasting glucose, blood urea 
nitrogen (BUN), creatinine, total serum protein, serum 
albumin, alkaline phosphatase (ALP), aspartate amino-
transferase, alanine aminotransferase, total bilirubin, er-
ythrocyte sedimentation rate (ESR), and C-reactive pro-
tein (CRP), were obtained. In addition, ANCA and CH50 
data were collected. Data related to poor prognosis out-
comes, including all-cause mortality, relapse, and 
end-stage renal disease (ESRD), were evaluated. Relapse 
was defined as recurrence or new onset disease requiring 
an increase in glucocorticoids and switching the im-
munosuppressant due to increased disease activity. ESRD 
was defined as a medical condition requiring renal re-
placement therapy for ＞3 months. The follow-up dura-
tion was defined as the interval between the date of the di-
agnosis of AAV and date of the last visit for living 
patients. For deceased patients, it was defined as the in-
terval between the date of diagnosis of AAV and the date 
of death, whereas for patients who had other poor out-
comes, it was defined as the interval starting from the 
date of diagnosis of AAV until the date of occurrence of 
the first poor outcome. 
Classification of variables: Tertiles based on the 
BVAS and two groups based on CH50
Since there is no clear BVAS criterion to define high dis-
ease activity, we divided the baseline BVAS into tertiles: 
high activity, intermediate activity, and low activity. We 
defined baseline high disease activity as a BVAS ≥13, 
which is the highest tertile in our data. Furthermore, we 
categorised the patients with AAV into two groups based 
on the calculated optimal cut-off of CH50 for high base-
line activity: patients with CH50 levels below the optimal 
cut-off were classified into the low-CH50 group, and 
those with CH50 levels equal to or above the cut-off were 
classified into the high-CH50 group.
Statistical analyses
All statistical analyses were conducted using SPSS soft-
ware (version 23 for Windows; IBM Corp., Armonk, NY, 
USA). Continuous variables were expressed as the me-
dian and interquartile range, whereas categorical variables 
were demonstrated as frequencies and percentages. The cor-
relation coefficient was obtained using Pearson correla-
tion analysis. The optimal cut-off was extrapolated by cal-
culating the receiver operator characteristic curve and se-
lecting the maximised sum of sensitivity and specificity. 
The relative risk (RR) was analysed using contingency ta-
bles and the chi-square test. The standardised correlation 
coefficient was assessed by multivariable linear re-
gression analysis using variables showing significant dif-
ferences in univariable analysis. The cumulative survival 
rates between the groups were compared using Kaplan–
Meier survival analysis with the log-rank test. p-values
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Table 1. Characteristics of AAV patients at diagnosis and 
during follow-up (n=101)
AAV patients Values
At the time of diagnosis 
Demographic data
    Age (yr)      62.0 (21.0)*
    Male sex         34 (33.7)
AAV subtypes 
    MPA         56 (55.4)
    GPA         28 (27.7)
    EGPA         17 (16.8)
ANCA positivity 
    MPO-ANCA (or P-ANCA) positivity         73 (72.3)
    PR3-ANCA (or C-ANCA) positivity         18 (17.8)
    Both ANCA positivity           5 (5.0)
    ANCA negativity         15 (14.9)
AAV-specific indices
    BVAS      12.0 (11.0)*
    FFS        1.0 (1.0)*
Clinical manifestations at diagnosis
    General         40 (39.6)
    Cutaneous         15 (14.9)
    Muco-membranous /Ocular           4 (4.0)
    Ear nose throat         48 (47.5)
    Pulmonary         67 (66.3)
    Cardiovascular         11 (10.9)
    Gastrointestinal           4 (4.0)
    Renal         61 (60.4)
    Nervous         25 (24.8)
Routine laboratory results 
    Urine protein creatinine ratio      1.42 (2.69)*
    Proteinuria         42 (41.5)
    Hematuria         49 (48.5)
    White blood cell count (/mm3) 8,910.0 (5,857.5)*
    Haemoglobin (g/dL)      11.3 (3.5)*
    Platelet count (×1,000/mm3)    307.5 (178.0)*
    Fasting glucose (mg/dL)    103.0 (28.5)*
    Blood urea nitrogen (mg/dL)      17.9 (22.8)*
    Serum creatinine (mg/dL)        0.9 (1.8)*
    Total protein (g/dL)        6.8 (1.2)*
    Serum albumin (g/dL)        3.7 (1.0)*
    Alkaline phosphatase (IU/L)      74.0 (35.8)*
    Aspartate aminotransferase (IU/L)      18.0 (7.0)*
    Alanine aminotransferase (IU/L)      15.0 (13.3)*
   Total bilirubin (mg/dL)        0.5 (0.4)*
    ESR (mm/hr)      63.5 (68.3)*
    CRP (mg/L)        8.0 (69.1)*
Complement
    CH50 (U/mL)      60.4 (17.9)*
    C3 (mg/dL)    113.0 (37.6)*
    C4 (mg/dL)      25.6 (12.4)*
During the follow-up period
Follow-up duration (mo)      26.4 (30.4)*
Table 1. Continued
AAV patients Values
Poor outcomes during follow-up
    All-cause mortality           9 (8.9)
    Duration until all-cause mortality (mo)      26.4 (30.4)*
    Relapse         31 (30.7)
    Duration until relapse (mo)      20.9 (25.5)*
    ESRD         20 (19.8)
    Duration until ESRD (mo)      20.8 (28.3)*
Medications administered during the 
follow-up period 
    Glucocorticoid         96 (95)
    Cyclophosphamide         52 (51.5)
    Rituximab         19 (18.8)
    Azathioprine         61 (60.4)
    Mycophenolate mofetil         13 (12.9)
    Tacrolimus           6 (5.9)
    Methotrexate           9 (8.9)
Values are expressed as the median (interquartile range) or 
number (%). AAV: ANCA-associated vasculitis, ANCA: 
antineutrophil cytoplasmic antibody, MPA: microscopic 
polyangiitis, GPA: granulomatosis with polyangiitis, EGPA: 
eosinophilic GPA, MPO: myeloperoxidase, P: perinuclear, 
PR3: proteinase 3, C: cytoplasmic, BVAS: Birmingham Vasculitis
Activity Score, FFS: Five-Factor score, ESR: erythrocyte 
sedimentation rate, CRP: C-reactive protein, CH50: total 
haemolytic complement activity, C3: complement 3, C4: 
complement 4, ESRD: end-stage renal disease. *Median 
(interquartile range).
＜0.05 were considered statistically significant.
RESULTS
Characteristics of AAV patients at diagnosis and 
during follow-up
At diagnosis, the median age of the 101 AAV patients 
was 62.0 years, and 34 patients were men. MPA was the 
most common AAV subtype (55.4%), and ANCA was 
positive in 86 patients. In addition, the median baseline 
BVAS and FFS were 12.0 and 1.0, respectively. Table 1 
presents the results of routine laboratory tests. The me-
dian CH50 level was 60.4 U/mL, and the median fol-
low-up duration was 26.4 months. All-cause death was 
reported in 9 patients during follow-up, whereas relapse 
and ESRD developed in 31 and 20 patients, respectively.
Correlation of continuous variables with CH50 at 
diagnosis
CH50 was significantly correlated with age and fasting 
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Figure 1. Optimal CH50 cut-off and relative risk. When the optimal CH50 cut-off at diagnosis for the high baseline activity of AAV based
on the BVAS (BVAS ≥13) was set below 62.1 U/m, AAV patients with CH50 ＜62.1 U/mL had a significantly higher risk for a high 
baseline activity of AAV based on the BVAS than those with CH50 ≥62.1 U/mL. CH50: total haemolytic complement activity, 
BVAS: Birmingham Vasculitis Activity Score, AAV: antineutrophil cytoplasmic antibody-associated vasculitis, CI: confidence inter-
val, RR: relative risk. 
Table 2. Correlation of continuous variables with the CH50 at 





Age (yr) 0.202 0.043
BVAS −0.241 0.015
FFS 0.030 0.762
White blood cell count (/mm3) −0.101 0.317
Haemoglobin (g/dL) −0.013 0.869
Platelet count (×1,000/mm3) −0.014 0.891
Fasting glucose (mg/dL) 0.299 0.002
Blood urea nitrogen (mg/dL) 0.083 0.408
Serum creatinine (mg/dL) 0.011 0.915
Total protein (g/dL) 0.102 0.308
Serum albumin (g/dL) 0.129 0.198
Alkaline phosphatase (IU/L) 0.013 0.900
Aspartate aminotransferase (IU/L) 0.039 0.699
Alanine aminotransferase (IU/L) 0.028 0.781
Total bilirubin (mg/dL) −0.003 0.974
ESR (mm/hr) 0.122 0.225
CRP (mg/L) −0.002 0.988
C3 (mg/dL) 0.061 0.555
C4 (mg/dL) 0.584 ＜0.001
CH50: total haemolytic complement activity, AAV: ANCA- 
associated vasculitis, ANCA: antineutrophil cytoplasmic
antibody, BVAS: Birmingham Vasculitis Activity Score, FFS: 
Five-Factor score, ESR: erythrocyte sedimentation rate, CRP: 
C-reactive protein, C3: complement 3, C4: complement 4.
glucose. Moreover, it was positively correlated with C4 
(r=0.584; p＜0.001) but not C3 (r=0.061; p=0.555). Of 
note, CH50 was negatively correlated with the BVAS (r=
−0.241; p=0.015) (Table 2). 
Optimal cut-off of CH50 at diagnosis 
The optimal CH50 cut-off at diagnosis for the high base-
line activity (based on the BVAS, BVAS ≥13) was set be-
low 62.1 U/mL, at which the sensitivity was 53.3% and 
the specificity was 75.6% (area, 0.358; 95% confidence 
interval [CI], 0.247 to 0.470) (Figure 1A). When we clas-
sified the AAV patients into two groups based on the cal-
culated CH50 cut-off, 59 of the 101 patients were sepa-
rated into the low-CH50 group. The high baseline activity 
of AAV, based on the BVAS, was identified more fre-
quently in the low-CH50 group than in the high-CH50 
group (52.5% vs. 23.8%; p=0.004). Furthermore, the 
low-CH50 group had a significantly higher risk for the 
high baseline activity of AAV than the high-CH50 group 
(RR, 3.543; 95% CI, 1.477 to 8.497) (Figure 1B). 
Linear regression analysis based on the BVAS at di-
agnosis 
In the univariable linear regression analysis, CH50, 
white blood cell and platelet counts, haemoglobin, BUN, 
serum albumin, ALP, alanine aminotransferase, ESR, and 
CRP were significantly correlated with the BVAS at 
diagnosis. However, in the multivariable analysis, only 
CH50 (β=−0.265; 95% CI, −0.173 to −0.036) and 
haemoglobin (β=−0.374; 95% CI, −1.842 to −0.261) 
were significantly associated with the BVAS at diagnosis 
(Table 3). 
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CH50 (U/mL) −0.241 0.015 −0.265 −0.173 to −0.036 0.003
C3 (mg/dL) −0.015 0.884
C4 (mg/dL) −0.140 0.175
Age (yr) 0.101 0.314
White blood cell count (/mm3) 0.198 0.047 0.032 0.000 to 0.000 0.791
Haemoglobin (g/dL) −0.500 ＜0.001 −0.374 −1.842 to −0.261 0.010
Platelet count (×1,000/mm3) 0.262 0.008 0.106 −0.006 to 0.015 0.402
Fasting glucose (mg/dL) −0.033 0.741
Blood urea nitrogen (mg/dL) 0.286 0.004 0.059 −0.054 to 0.098 0.575
Serum creatinine (mg/dL) 0.179 0.074
Total protein (g/dL) 0.035 0.731
Serum albumin (g/dL) −0.440 ＜0.001 −0.021 −2.951 to 2.591 0.898
Alkaline phosphatase (IU/L) 0.225 0.025 0.185 −0.004 to 0.061 0.084
Aspartate aminotransferase (IU/L) −0.120 0.234
Alanine aminotransferase (IU/L) −0.228 0.022 −0.093 −0.116 to 0.047 0.399
Total bilirubin (mg/dL) −0.151 0.135
ESR (mm/hr) 0.327 0.001 0.175 −0.014 to 0.075 0.180
CRP (mg/L) 0.237 0.017 −0.132 −0.049 to 0.020 0.401
BVAS: Birmingham Vasculitis Activity Score, AAV: ANCA-associated vasculitis, ANCA: antineutrophil cytoplasmic antibody, 
CH50: total haemolytic complement activity, C3: complement 3, C4: complement 4, ESR: erythrocyte sedimentation rate, CRP:
C-reactive protein. 
Poor-outcome-free survival rates during follow-up
With regard to poor outcomes, the low-CH50 group ex-
hibited a lower relapse-free survival rate than the high- 
CH50 group; however, this difference did not reach sig-
nificance (p=0.082). Additionally, there were no sig-
nificant differences in the ESRD-free survival rate be-
tween the two groups (Figure 2).
Association between hypocomplementemia and 
baseline high disease activity and poor-outcomes
We analyzed whether disease activity was associated 
with hypocomplementemia, defined as CH50, C3, or C3 
below the reference range. AAV patients with hypo-
complementemia showed a significantly higher risk of 
high baseline activity of AAV, based on the BVAS, than 
those without hypocomplementemia (RR, 8.821; 95% 
CI, 2.323∼33.501) (Figure 3). In addition, regarding 
poor outcomes during follow-up, AAV patients with hy-
pocomplementemia exhibited a significantly lower cu-
mulative ESRD-free survival rate than those without hy-
pocomplementemia (p=0.002). However, no significant 
differences were observed in both the cumulative pa-
tients’ overall and relapse-free survival rates between the 
groups (p=0.767 and 0.055, respectively) (Figure 4).
DISCUSSION 
In this study, we investigated whether CH50 levels at di-
agnosis could reflect the baseline activity and predict the 
prognosis of AAV. At the diagnosis of AAV, CH50 was in-
versely correlated with the BVAS, and based on our data, 
the suggested cut-off CH50 level to predict severe disease 
of AAV was 62.1 U/mL. Summarising the results of this 
study, the following conclusions were drawn: the low 
CH50 level at diagnosis was associated with severe dis-
ease of AAV; however, it did not predict the occurrence of 
poor outcomes of AAV.
Among C3 and C4, only C4 positively correlated with 
CH50, which primarily reflected the activation of the clas-
sical complement pathway. At the beginning of this study, 
C3 was also expected to be well-correlated with CH50 be-
cause the alternative complement pathway is known to be 
mainly involved in the pathophysiology of AAV compared 
with the classical complement pathway. However, no cor-
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Figure 2. Comparison of poor-outcome-free survival rates. 
There were no significant differences in the relapse-free and 
ESRD-free survival rates between the AAV patients with 
CH50 ＜62.1 U/mL and those with CH50 ≥62.1 U/mL. 
CH50: total haemolytic complement activity, ESRD: 
end-stage renal disease, AAV: antineutrophil cytoplasmic an-
tibody-associated vasculitis. 
Figure 3. Relative risk of high disease activity regarding 
hypocomplementemia. AAV patients with hypocomplementemia,
defined as below reference range of CH50, C3, or C4, showed
significantly higher risk for a high baseline activity of AAV 
(BVAS≥13). CH50: total haemolytic complement activity, 
AAV: antineutrophil cytoplasmic antibody-associated vasculi-
tis, BVAS: Birmingham Vasculitis Activity Score.
relation was found between CH50 and C3. Therefore, to 
validate this finding, a method of interpreting ‘which 
complement pathway is activated’ was adopted, based on 
the patterns of increases and decreases in CH50, C3, and 
C4 levels. In this method, when CH50 and C4 levels were 
reduced, regardless of C3 levels, we found that the classi-
cal complement pathway was predominantly involved. 
Concurrently, when CH50 and C3 levels were reduced 
and the C4 level was normal, we considered that the alter-
native complement pathway was more frequently in-
volved [15]. In the present study, 6 out of 101 patients 
had a CH50 level below the normal reference range ac-
cording to the haemolysis method, and all these patients 
exhibited a high baseline activity of AAV based on the 
BVAS. Furthermore, three of the six patients with a CH50 
level below the normal reference range exhibited low C3 
or C4. One patient showed low C3, which indicated alter-
native complement pathway activation. However, anoth-
er patient demonstrated low C4, and the third patient ex-
hibited both low C3 and C4, which suggested a classical 
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Figure 4. Comparison of poor-outcome-free survival rates 
regarding hypocomplementemia. There were no significant 
differences in the cumulative patients’ overall and re-
lapse-free survival rates between the AAV patients with or 
without hypocomplementemia. However, AAV patients 
with hypocomplementemia exhibited a significantly lower 
cumulative ESRD-free survival rate than those without 
hypocomplementemia. AAV: antineutrophil cytoplasmic 
antibody-associated vasculitis, ESRD: end-stage renal 
disease. 
complement pathway activation. With these results, we 
could not conclude which complement pathway was pre-
dominantly contributing to the high baseline activity of 
AAV.
Fukui et al. [9] reported that hypocomplementemia, 
which was defined as a low CH50, C3, or C4 level, was as-
sociated with death and organ damage in patients with 
AAV. In this study, we investigated whether hypo-
complementemia could reflect the high baseline activity 
of AAV and predict poor outcomes. Our data showed that 
AAV patients with hypocomplementemia showed a sig-
nificantly higher risk of high baseline activity (based on 
the BVAS, BVAS ≥13) and significantly lower cumulative 
ESRD-free survival than those without hypocomplementemia. 
However, unlike that in the previous study [9], no sig-
nificant differences were observed in both the cumulative 
patients’ overall and relapse-free survival rates between 
the groups. Further studies are needed to analyze these 
discrepancies and conclude an association between hypo-
complementemia and disease activity and poor outcomes 
of AAV. Moreover, we examined whether low C3 or low 
C4 could reflect the baseline activity of AAV and predict 
ESRD occurrence (data not presented). We found that 
AAV patients with low C3 exhibited a significantly higher 
risk of high baseline activity of AAV, based on the BVAS, 
than those with normal C3 levels (RR, 5.129; 95% CI, 
1.291∼20.382). Furthermore, a low C3 value at diag-
nosis had the predictive potential for ESRD occurrence 
during follow-up, compared with a normal C3 (p=0.001). 
Conversely, a low C4 value at diagnosis could neither re-
flect a high baseline activity of AAV based on the BVAS 
nor predict the occurrence of ESRD during follow-up in 
AAV patients (p=0.069 and 0.061, respectively). 
Consequently, we conclude that low CH50 and low C3 
among patients with hypocomplementemia reflect the 
baseline activity, whereas only low C3 predicts ESRD oc-
currence during follow-up. 
In this study, we used a CH50 value of 61.2 U/mL, rather 
than the reference range, as the optimal cut-off for the 
high baseline activity of AAV. In the univariable analysis, 
Jung Yoon Pyo et al.
92 J Rheum Dis Vol. 28, No. 2, April, 2021
at diagnosis, both CH50 ＜62.1 U/mL (OR, 3.543; 95% 
CI, 1.477∼8.497) and low C3 (OR, 5.129; 95% CI ,1.291
∼20.382) were significantly associated with the high 
baseline activity of AAV based on the BVAS. However, in 
the multivariable analysis with two variables, CH50 
＜62.1 U/mL (OR, 3.320; 95% CI, 1.327∼8.306) was 
significantly associated with high baseline activity of 
AAV; however, low C3 (OR, 3.389; 95% CI, 0.812∼
12.147) was not. Therefore, CH50 below the optimal 
cut-off is more efficient than low C3, reflecting the high 
baseline activity of AAV based on the BVAS; however, for 
predicting poor renal outcomes, low C3 at diagnosis is 
better than CH50 below the optimal cut-off at diagnosis.
A notable strength of this study is that we provided a 
novel cut-off value for CH50, which was correlated with 
baseline disease activity. Furthermore, our patient pop-
ulation was immunosuppressant-naïve and diagnosed at 
a single centre, which can minimise the confounding 
factor. However, our study had the following limitations. 
First, the number of study subjects was not large enough 
to generalise and apply the results of our study to all pa-
tients with AAV. Second, because we do not have separate 
validation group, the cut-off value of CH50 as 61.2 U/mL 
should be validated in other AAV cohorts in future 
studies. In addition, it was conducted as a retrospective 
study. Hence, alternative complement pathway activation 
(AH50) and Factor B could not be evaluated in this study. 
Inclusion of AH50 and Factor B might have enabled a 
more accurate interpretation of the CH50, C3, and C4 
patterns [5,15]. 
CONCLUSION
CH50 levels may reflect the baseline disease activity in 
AAV patients. Future studies with a larger patient pop-
ulation may provide more reliable data regarding disease 
prognosis associated with CH50, as there was a tendency 
toward an association between CH50 and the relapse-free 
survival rate in this study.
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